Tetrylammonium

Tetrylammonium

SCHEMBL2452722

CC[N+](CC)(CC)CC.CC[N+](CC)(CC)CC.O=C([O-])C=CC(=O)[O-]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Tetrylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BBOX1 O75936 4/20 0.46
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
KCNA1 Q09470 1/20 0.44
KDM4E B2RXH2 1/20 0.42
PMP22 Q01453 1/20 0.42
ATM Q13315 1/20 0.42
CA1 P00915 2/20 0.37
CA9 Q16790 1/20 0.37
FFAR3 O14843 2/20 0.33
HDAC3 O15379 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC8 Q9BY41 2/20 0.33
CES2 O00748 1/20 0.30
CES1 P23141 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrylammonium SCHEMBL2353697 1.00 BBOX1 (0.46) BBOX1TSHRNFKB1KCNA1KDM4E
Tetrylammonium SCHEMBL2348762 1.00 BBOX1 (0.46) BBOX1TSHRNFKB1KCNA1KDM4E
Tetrylammonium SCHEMBL2351931 0.97 BBOX1 (0.44) BBOX1TSHRNFKB1KCNA1KDM4E
Tetrylammonium SCHEMBL2346208 0.97 BBOX1 (0.44) BBOX1TSHRNFKB1KCNA1KDM4E
Tetrylammonium SCHEMBL11155692 0.97 BBOX1 (0.44) BBOX1TSHRNFKB1KCNA1KDM4E
Tetrylammonium SCHEMBL3864261 0.97 BBOX1 (0.44) BBOX1TSHRNFKB1KCNA1KDM4E
Tetrylammonium SCHEMBL2346200 0.97 BBOX1 (0.44) BBOX1TSHRNFKB1KCNA1KDM4E
Tetrylammonium SCHEMBL2452720 0.91 TSHR (0.41) BBOX1TSHRNFKB1KCNA1KDM4E
Tetrylammonium SCHEMBL2351488 0.91 TSHR (0.41) BBOX1TSHRNFKB1KCNA1KDM4E
Tetrylammonium SCHEMBL2349569 0.91 TSHR (0.41) BBOX1TSHRNFKB1KCNA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118206453-A Preparation method of tetraethylammonium maleate 江苏国泰超威新材料有限公司 2024-06-18 CN claimed
CN-115312330-B Super capacitor electrolyte and super capacitor using same 江苏国泰超威新材料有限公司 2022-12-30 CN claimed
CN-115312330-A Super capacitor electrolyte and super capacitor using same 江苏国泰超威新材料有限公司 2022-11-08 CN claimed
EP-3481878-A1 AMINE COMPOSITION USEFUL FOR MAKING POLYURETHANE FOAM Evonik Degussa GmbH (DE) 2019-05-15 EP claimed
WO-2018013590-A1 AMINE COMPOSITION USEFUL FOR MAKING POLYURETHANE FOAM EVONIK DEGUSSA GMBH (DE) 2018-01-18 WO claimed
EP-2003157-A2 Tetraalkylammonium carboxylate salts as trimerization catalysts for spray foam applications Air Products and Chemicals, Inc. (US) 2008-12-17 EP claimed
US-4885115-A Liquid electrolyte for use in electrolytic capacitor NIPPON CHEMI-CON CORPORATION (JP) 1989-12-05 US claimed
JP-1214107-A None JP disclosed
US-20260118767-A1 REVERSE PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-04-30 US disclosed
EP-4700067-A1 COMPOSITION FOR FORMING SILICON-CONTAINING FILM, METHOD FOR FORMING FILM, AND SUPERSTRATE SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-02-25 EP disclosed
US-20260044081-A1 COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-02-12 US disclosed
EP-4692941-A2 COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS Shin-Etsu Chemical Co., Ltd. (JP) 2026-02-11 EP disclosed
US-20260029706-A1 COMPOSITION FOR FORMING SILICON-CONTAINING FILM, METHOD FOR FORMING FILM, AND SUPER STRAIGHT SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-01-29 US disclosed
EP-0971427-A1 An ionic conductive polymer electrolyte MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 2000-01-12 EP disclosed
US-5538811-A ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER, DOUBLE LAYER CAPACITORS, LITHIUM BATTERIES MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1996-07-23 US disclosed
EP-0579921-A1 An ionic conductive polymer electrolyte MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1994-01-26 EP disclosed
US-4885115-A Liquid electrolyte for use in electrolytic capacitor NIPPON CHEMI-CON CORPORATION (JP) 1989-12-05 US disclosed
JP-H01214107-A ELECTROLYTIC CAPACITOR ASAHI GLASS CO LTD 1989-08-28 JP disclosed
US-4734821-A AMMONIUM SALT OF CARBOXYLIC ACID ASAHI GLASS COMPANY LTD. (JP) 1988-03-29 US disclosed
EP-0227433-A2 Electrolyte solution of quaternary ammonium salt for electrolytic capacitor MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1987-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260029706-A1 COMPOSITION FOR FORMING SILICON-CONTAINING FILM, METHOD FOR FORMING FILM, AND SUPER STRAIGHT SMC2, F12, SMC1A BBOX1 2884/4885TSHR 3510/4885NFKB1 4368/4885
US-20260118767-A1 REVERSE PATTERNING PROCESS EFNA1, EPHA4, ETV6 BBOX1 4582/4885TSHR 770/4885NFKB1 3949/4885
US-20260044081-A1 COMPOSITION FOR FORMING SILICON-CONTAINING RESIST FILM AND PATTERNING PROCESS SMC1A, SPOUT1, LBR BBOX1 2439/4885TSHR 446/4885NFKB1 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.